2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Pcv20: new trials by email Literature Review of Pcv20 trials Research Report on Pcv20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine - Pneumococcal Vaccines | Phase 1 / Phase 2 | Completed | Vaxcyte, Inc. | 1015 | 2023-11-08 | 2025-07-28 |
| A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants AFX3772, Prevnar 13, Prevnar 20 - Pneumonia, Bacterial, Pneumococcal Infections | Phase 2 | Completed | GlaxoSmithKline | 388 | 2022-06-16 | 2026-10-09 |
Infections (1) · Pneumococcal Infections (1) · Pneumonia (1) · Pneumonia, Bacterial (1) · Pneumonia, Pneumococcal (1) · Streptococcal Infections (1)
GlaxoSmithKline (1) · Vaxcyte, Inc. (1)
United States (2) · Puerto Rico (1)
2023 (1)